Introduction
The prognosis and the quality of life of localized osteosarcoma patients greatly improved over the last 30 years with overall survival rates increasing from 10% with surgery alone, usually amputation, 1 to 70% with the introduction of neoadjuvant chemotherapy and limbsparing surgery. 2, 3 However, recurrent disease occurs in approximately 30-40% of patients with non-metastatic osteosarcoma of the extremities. Recurrence is most common in the lungs. The mean 5-year post-relapse survival rate is about 28%, but some groups of patients have a 0% overall survival. 4 Patients with metastatic disease at diagnosis have a poor prognosis with a 5-year event-free survival of 30%. 5, 6 Among this group, the prognosis of patients with multifocal osteosarcoma [7] [8] [9] or with axial metastases 6 is the most severe.
Indications and risk factors
Among patients with osteosarcoma, the prognosis is severe in (a) poor responders to neoadjuvant chemotherapy, (b) patients without the possibility of primary tumor resection, (c) patients with metastases at diagnosis, in particular bone metastases and (d) recurrent disease with unresectable metastases or more than two resectable lung nodules. 4 Because of its poor prognosis, this group of patients represents the target for new therapeutic strategies.
Results

High-dose chemotherapy
The use of high-dose chemotherapy with subsequent hemopoietic PBSC infusion has been investigated in a few studies. Thirty-two patients with metastatic osteosarcoma were included in an Italian Sarcoma Group (ISG) study. Two courses of high-dose carboplatin and etoposide were followed by autologous stem cell rescue: the 3-year overall survival was 20% with a 3-year disease-free survival of 12%. 10 Similar data were obtained by the Cooperative German-Austrian-Swiss Osteosarcoma Study Group by using different drugs in the high-dose setting. 11 Importantly, in the first group of patients there was a high remission rate, although with a low disease-free survival. 10 Therefore, this approach might be used to induce remission, but different strategies, such as immunotherapy, should be explored to maintain the remission.
Radiometabolic treatment
Samarium-153 ethylenediamine tetramethylene phosphonic acid (EDTMP), a radio-labeled phosphonate, was developed for palliative treatment of bone metastases with a standard palliative dose of 1 mCi/kg.
Attempts have been made to improve its activity by increasing the dose.
Franzius et al. 12 reported the treatment of six patients with 4 mCi/kg: 36 months later, one patient was still free of progression. Anderson et al.
13 treated 30 patients with 30 mCi/kg followed by PBSC support reporting no data on disease efficacy. Minimal non-hematologic side effects were evidenced.
We treated seven patients with poor prognosis osteosarcoma by administering samarium-153-EDTMO 10 mCi/kg and subsequent PBSCs. Five patients had progression of disease at a median of 2 months and died of disease at a median of 5 months after treatment. Two patients were still alive with stable disease at 7 and 12 months. Studies on the use of samarium-153-EDTMO are limited and not homogeneous. No conclusive data can be drawn, but in a new protocol of the ISG and AIEOP (Italian Association of Pediatric Hemato-Oncology), samarium-153-EDTMO is used after chemotherapy to consolidate the tumor response.
Immunotherapy and non-myeloablative allo-SCT The IL-2 has been investigated as an immunotherapeutic approach on 18 pediatric patients affected by osteosarcoma and treated with four courses of IL-2 and polychemotherapy. The results showed an immune activation in response to IL-2.
14 Non-myeloablative allo-SCT is a form of immunotherapy linked to minor HLA antigens, which has been shown to be efficient in different solid tumors. [15] [16] [17] [18] We reported the evidence of metastases regression in a 12-year-old boy with advanced osteosarcoma, in which the immunological anti-osteosarcoma effect was independent of the GvHD reaction. 17 Goi et al. 19 treated a nine-year-old boy with metastatic disease with reduced intensity transplantation. The patient developed a grade III GvHD and was alive showing no evidence of relapse 67 months after the hemopoietic SCT. Kounami et al. 20 treated a 14-yearold boy with refractory osteosarcoma: the patient relapsed on day þ 59 after transplantation and died of disease on day þ 197.
Since no large series of studies are available, no conclusions can be drawn on the effectiveness of nonmyeloablative SCT in osteosarcoma.
New experimental drugs
Recent studies have been published on drugs not commonly used in first-line treatments of osteosarcoma.
Topotecan was employed as window therapy in 26 metastatic osteosarcoma patients at diagnosis followed by multi-agent chemotherapy, but it did not 
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show an effective improvement as compared to the traditional chemotherapy. 21 Gemcitabine was employed alone with minimal response, 22 but in one study it was employed together with docetaxel in four patients with osteosarcoma, in which two partial responses have been observed. 23 Ecteinascidin 743 has been employed alone in pretreated recurrent osteosarcoma patients with dismal results. 24 Interferon as single-agent adjuvant therapy has been used for 18 months up to 5 years on 89 osteosarcoma patients in CR. The 10-year metastases-free survival was 39% with a median follow-up of 12 years. 25 The lack of a control group precludes conclusions.
Conclusions
These data indicate that only the combination of several strategies, such as intensive chemotherapy to induce remission followed by immunotherapy to maintain the remission status, might improve the prognosis of these patients.
On this basis, the AIEOP and the ISG devised a clinical trial for osteosarcoma patients with unresectable relapse consisting of three different phases:
(a) Induction phase with chemotherapy and mobilization and PBSC apheresis to induce a CR or PR of the disease. (b) High-dose samarium-153-EDTMO followed by PBSC reinfusion in patients with lesions positive at bone scintigraphy. In negative patients, the conditioning regimens consist of high-dose chemotherapy (carboplatin and VP-16). (c) Immunotherapy phase in which patients with an HLA-identical sibling receive a non-myeloablative hemopoietic SCT (eventually followed by donor lymphocyte infusion (DLI)) and patients without an HLA-identical sibling receive 12 cycles of low-dose IL-2.
Future perspectives
T-cell therapy has attracted a great deal of interest in the treatment of viral infections, EBV-associated tumors and relapses of hematological disease. The persistence of adoptively transferred T cells and the reconstitution of virus-specific immunity with no noticeable side effects have been amply demonstrated. Many solid tumors, such as sarcomas, express tumorspecific antigens on their surface, which can serve as targets for immune effector T cells. Nevertheless, the immune surveillance against clinically manifested tumors is relatively inefficient, and the number and the function of DCs are dramatically reduced in patients with head and neck squamous cell carcinoma, breast, renal, colon and prostate cancer. [26] [27] [28] The identification of tumor antigens and their recognition by tumor-specific lymphocytes have fueled the development of immunotherapeutic strategies in cancer. 29, 30 Ex vivo generation/expansion, followed by in vivo infusion, of CTL lines or clones, able to selectively kill tumor cells, represents a potentially successful therapeutic approach to overcome the failure of patients to develop an efficient antitumor immune response. 31 Recently, the expression of MAGE, SSX and SART-3 family antigens has been identified in osteosarcoma cell lines and in fresh osteosarcoma tissues, allowing the development of immunotherapeutic strategies in high-grade osteosarcoma patients as well.
In this context, we intend to generate tumor antigenspecific CTLs by stimulating patients' PBMCs or CD8-enriched populations with DCs loaded with irradiated autologous apoptotic tumor cells or autologous tumor cell lysates (Figure 1) .
The novelty and relevance of this project consist in assessing the frequency by which antitumor T-cell lines can be obtained ex vivo and in identifying which of the already known tumor antigens are recognized by these T-cell lines.
The fate and function of tumor-reactive CTLs will be evaluated by analyzing the frequency of tumor-reactive CTL precursors (p) and IFN-g-secreting PBMCs by Elispot Assay, phenotype and cytokine release following CTL generation (Figures 2a and b) . 
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